is a vaccine indicated for active immunization against diphtheria, tetanus, pertussis, ๐ฝ๐ผ๐น๐ถ๐ผ๐บ๐๐ฒ๐น๐ถ๐๐ถ๐ and invasive disease due to Haemophilus influenzae type b. Pentacel is approved for use as a four dose series in children 6 weeks through 4 years of age (prior to 5th birthday).
The following adverse events were included based on one or more of the following factors: severity, frequency of reporting, or strength of evidence for a causal relationship to Pentacel.
โข Cardiac disorders
โข Cyanosis
โข Gastrointestinal disorders
โข Vomiting, diarrhea
โข General disorders and administration site conditions
โข Injection site reactions (including inflammation, mass, abscess and sterile abscess), extensive swelling of the injected limb (including swelling that involved adjacent joints), vaccination failure/therapeutic response decreased (invasive H. influenzae type b disease)
โข Immune system disorders
โขAnaphylaxis/anaphylactic reaction, hypersensitivity (such as rash and urticaria)
โข Infections and infestations
โข Meningitis, rhinitis, viral infection
โข Metabolism and nutrition disorder
โข If Guillain-Barrรฉ syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barrรฉ
syndrome may be increased following Pentacel.